<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">Cerebral vasospasm</z:e> is an important syndrome that afflicts 30% of patients in the aftermath of, and secondary to, <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Starting approximately one week after the <z:mp ids='MP_0001914'>hemorrhage</z:mp>, the condition worsens the prognosis of the <z:mp ids='MP_0001914'>hemorrhage</z:mp> significantly </plain></SENT>
<SENT sid="2" pm="."><plain>Apart from general supportive care, no treatment exists for <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>During the past 50 years, it was thought that the <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> that signifies poor outcome is more or less exclusively caused by arterial narrowing </plain></SENT>
<SENT sid="4" pm="."><plain>However, this idea has recently been challenged by the failure of the drug clazosentan to improve patient outcome, despite reversing vasoconstriction </plain></SENT>
<SENT sid="5" pm="."><plain>In this article, we discuss the opinion that factors other than vasoconstriction are important in the pathophysiology and prognosis of <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Such factors include global <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, disruption of the blood-brain barrier, activation of apoptotic and inflammatory pathways, and cortical spreading <z:hpo ids='HP_0000716'>depression</z:hpo> </plain></SENT>
</text></document>